Droxidopa

CHTP - News announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 8,008,285 entitled "Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia."

unknown title 2011

Its key compounds are an antifolate to treat rheumatoid arthritis and Droxidopa, which is used for the treatment of neurogenic orthostatic hypotension.

Dallas Business News - Local Dallas News | Dallas Business Journal 2010

Droxidopa is a synthetic catecholamine that is directly converted to norepinephrine NE via decarboxylation, resulting in increased levels of NE in the nervous system, both centrally and peripherally.

unknown title 2011

Droxidopa, a synthetic amino acid, is converted by the body into norepinephrine and, as a prodrug of NE, provides replacement therapy for NE deficiency.

unknown title 2011

In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051.

unknown title 2011

Droxidopa is a synthetic catecholamine that is directly converted to norepinephrine NE via decarboxylation, resulting in increased levels of NE in the nervous system, both centrally and peripherally.

unknown title 2011

Droxidopa, the lead investigational agent in Chelsea Therapeutics' broad pipeline, is currently in Phase III clinical trials for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary autonomic failure -- a group of diseases that includes Parkinson's disease, multiple system atrophy (MSA) and pure autonomic failure (PAF).

unknown title 2011

Droxidopa is also being studied for the treatment of fibromyalgia in an ongoing Phase II trial and completed a Phase II trial in intradialytic hypotension IDH study with positive results.

unknown title 2011

In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051.

unknown title 2011

In addition to Droxidopa, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051.

unknown title 2011